Improving how the immune system recognizes and fights cancer using targeted nanoparticles
Enhancing Tumor Antigen Presentation with Complement Targeted Nanoparticles
['FUNDING_R15'] · UNIVERSITY OF ALASKA ANCHORAGE · NIH-10360368
This study is exploring a new way to help your immune system fight cancer by using special tiny bubbles that deliver cancer-related proteins to immune cells, making them work better together to attack tumors.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALASKA ANCHORAGE (nih funded) |
| Locations | 1 site (ANCHORAGE, UNITED STATES) |
| Trial ID | NIH-10360368 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the immune response against cancer by improving the way tumor antigens are presented to immune cells. It utilizes a novel liposome delivery system, known as C3-liposomes, which targets various antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. By encapsulating tumor antigens and immune-activating compounds within these liposomes, the goal is to stimulate a stronger immune response that can effectively eliminate tumors. The research aims to identify the best combinations of antigens and immune stimulators to optimize this process.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who may benefit from improved immunotherapy options.
Not a fit: Patients with non-solid tumors or those who are not eligible for immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance the body's ability to fight tumors.
How similar studies have performed: Preliminary results from similar approaches using targeted nanoparticles have shown promise in animal models, indicating potential for success in human applications.
Where this research is happening
ANCHORAGE, UNITED STATES
- UNIVERSITY OF ALASKA ANCHORAGE — ANCHORAGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KULLBERG, MAX PETER — UNIVERSITY OF ALASKA ANCHORAGE
- Study coordinator: KULLBERG, MAX PETER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.